BRAF-Mutant Metastatic Melanoma Cell Lines

Melanoma cell lines WM3734, 1205 LU, Mel1617 and 451 LU were kindly gifted by M. Herlyn from the Wistar Institute (Philadelphia, USA)^{20 (link)}. A375, SK-MEL 19 and SK-MEL 28 cell lines were purchased from ATCC. All melanoma cells used were BRAF^V600E-mutated metastatic melanoma cell lines and exhibit different TP53 gene mutational status. According to the categories and data previously described and available at IARC TP53 data base^{21 (link)}, A375, WM3734, 1205Lu and Mel1617 are TP53 wild-type cell lines, TP53 mutation of the SK-MEL 28 (TP53 L145R) and 451Lu (TP53 Y220C) cell line leads to the expression of a non-functional p53 protein and the TP53 mutation of the SK-MEL 19 cell line (TP53 N131K) still enables partially functional p53 protein expression. Melanoma cell lines were cultured as described previously^{22 (link)}. MAPKi-resistant melanoma cell lines were generated by treatment with continuously increasing concentration of the BRAF inhibitor (BRAFi) vemurafenib (up to 2 µM) or additionally with the MEK inhibitor (MEKi) trametinib (up to 50 nM) for several months.